Extent of lymphadenectomy and outcome for patients with stage I nonsmall cell lung cancer

Cancer ◽  
2009 ◽  
Vol 115 (4) ◽  
pp. 851-858 ◽  
Author(s):  
John M. Varlotto ◽  
Abram Recht ◽  
Margaret Nikolov ◽  
John C. Flickinger ◽  
Malcolm M. DeCamp
Keyword(s):  
Lung Cancer ◽  
Cell Lung Cancer ◽  
Nonsmall Cell Lung Cancer ◽  
Stage I

scholarly journals Management of stage I and II nonsmall cell lung cancer

2016 ◽  
Vol 49 (1) ◽  
pp. 1600764 ◽  
Author(s):  
Fiona McDonald ◽  
Michèle De Waele ◽  
Lizza E. L. Hendriks ◽  
Corinne Faivre-Finn ◽  
Anne-Marie C. Dingemans ◽  
...  
Keyword(s):  
Lung Cancer ◽  
High Risk ◽  
Adjuvant Chemotherapy ◽  
Cell Lung Cancer ◽  
Targeted Therapies ◽  
Nonsmall Cell Lung Cancer ◽  
Stage I ◽  
Ageing Population ◽  
Randomised Trials ◽  
Long Term Outcome

The incidence of stage I and II nonsmall cell lung cancer is likely to increase with the ageing population and introduction of screening for high-risk individuals. Optimal management requires multidisciplinary collaboration. Local treatments include surgery and radiotherapy and these are currently combined with (neo)adjuvant chemotherapy in specific cases to improve long-term outcome. Targeted therapies and immunotherapy may also become important therapeutic modalities in this patient group. For resectable disease in patients with low cardiopulmonary risk, complete surgical resection with lobectomy remains the gold standard. Minimally invasive techniques, conservative and sublobar resections are suitable for a subset of patients. Data are emerging that radiotherapy, especially stereotactic body radiation therapy, is a valid alternative in compromised patients who are high-risk candidates for surgery. Whether this is also true for good surgical candidates remains to be evaluated in randomised trials. In specific subgroups adjuvant chemotherapy has been shown to prolong survival; however, patient selection remains important. Neoadjuvant chemotherapy may yield similar results as adjuvant chemotherapy. The role of targeted therapies and immunotherapy in early stage nonsmall cell lung cancer has not yet been determined and results of randomised trials are awaited.

Stage I Nonsmall Cell Lung Cancer up to 3 cm in Diameter: Prognostic Factors

2004 ◽  
Vol 40 (3) ◽  
pp. 110-113 ◽  
Author(s):  
J. Padilla ◽  
V. Calvo ◽  
J.C. Peñalver ◽  
C. Jordá ◽  
J. Escrivá ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Prognostic Factors ◽  
Cell Lung Cancer ◽  
Nonsmall Cell Lung Cancer ◽  
Stage I

scholarly journals Macrophage Inhibitory Cytokine-1 as a Novel Diagnostic and Prognostic Biomarker in Stage I and II Nonsmall Cell Lung Cancer

2016 ◽  
Vol 129 (17) ◽  
pp. 2026-2032 ◽  
Author(s):  
Yu-Ning Liu ◽  
Xiao-Bing Wang ◽  
Teng Wang ◽  
Chao Zhang ◽  
Kun-Peng Zhang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cell Lung Cancer ◽  
Prognostic Biomarker ◽  
Nonsmall Cell Lung Cancer ◽  
Stage I

The risk of second primary tumors after resection of stage I nonsmall cell lung cancer

2003 ◽  
Vol 76 (4) ◽  
pp. 1001-1008 ◽  
Author(s):  
David Rice ◽  
Hyung-Woo Kim ◽  
Anita Sabichi ◽  
Scott Lippman ◽  
J.Jack Lee ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cell Lung Cancer ◽  
Nonsmall Cell Lung Cancer ◽  
Stage I ◽  
Second Primary ◽  
Primary Tumors ◽  
Second Primary Tumors

scholarly journals Wedge resection and radiofrequency ablation for stage I nonsmall cell lung cancer

2015 ◽  
Vol 45 (4) ◽  
pp. 1089-1097 ◽  
Author(s):  
Marcello C. Ambrogi ◽  
Olivia Fanucchi ◽  
Paolo Dini ◽  
Franca Melfi ◽  
Federico Davini ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Radiofrequency Ablation ◽  
Cell Lung Cancer ◽  
Wedge Resection ◽  
Nonsmall Cell Lung Cancer ◽  
Disease Recurrence ◽  
Stage I ◽  
Disease Free Interval ◽  
Free Interval ◽  
Disease Free

The main aim of this study was to compare radiofrequency ablation (RFA) and wedge resection in terms of disease recurrence and survival, as intent-to-treat therapy for stage I nonsmall cell lung cancer (NSCLC) in marginal or non-surgical candidates.121 high-risk patients, treated for stage I NSCLC with wedge resection (n=59) or RFA (n=62) in a 7-year period, were analysed. Age, sex, comorbidity score, performance status, forced expiratory volume in 1 s and forced vital capacity values, body mass index, T-stage and histology were evaluated as possible risk factors affecting disease recurrence and survival.At a median follow-up of 36 and 42 months for wedge resection and for RFA (p=0.232), local recurrence rate was 2 and 23%, respectively (p=0.002). The 1-, 2- and 5-year overall survival (disease-free interval) rates were 100% (96%), 96% (90%) and 52% (76%) for wedge resection, and 93% (87%), 72% (63%), and 35% (55%) for RFA (p=0.044 and p=0.01, respectively). None of the analysed parameters was found to be risk factor for disease recurrence and survival, except stage T2, which significantly affected disease-recurrence, overall and cancer-related survival and disease-free interval in the RFA group.Whenever possible, surgical resection, even if limited, should be preferred due to its higher disease control and survival rates. RFA can be considered a valid option for inoperable patients, especially for those with stage T1N0.

scholarly journals Thymidylate synthase in situ protein expression and survival in stage I nonsmall-cell lung cancer

Cancer ◽  
2008 ◽  
Vol 112 (12) ◽  
pp. 2765-2773 ◽  
Author(s):  
Zhong Zheng ◽  
Xueli Li ◽  
Michael J. Schell ◽  
Tingan Chen ◽  
David Boulware ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Protein Expression ◽  
Cell Lung Cancer ◽  
Thymidylate Synthase ◽  
Nonsmall Cell Lung Cancer ◽  
Stage I
Sign in / Sign up

Export Citation Format

Share Document